Sole Source Letter - Governmental Customer.pdf
PDF 437 KB Posted
- Solicitation number
- N0018320Q0157
View the file
Other files
| File | Type | Posted |
|---|---|---|
| N0018320Q0157 Amendment 0001.pdf | ||
| N0018320Q0157 Solicitation.pdf | ||
| Jand A Signed Redacted.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
1425 U.S. Route 206, Bedminster, NJ 07921 • 908.238.6600 www.mnk.com
September 21, 2020
RE: INOtherapy - Sole Source Statement
Dear Valued Customer:
INO Therapeutics LLC, a Mallinckrodt company, is the sole source provider and manufacturer of nitric oxide-based inhalation therapy, INOtherapy®, in the United States.
INOtherapy includes our pharmaceutical, INOmax® (nitric oxide) for inhalation (NDC numbers 64693-002-01 and 64693-002-02).
INO’s provision of INOtherapy to Customer is hereby expressly made conditional on the terms and conditions of the FSS Contract No. V797D-60737 between INO Therapeutics and the Department of Veterans Affairs dated September 1, 2017 (the “FSS Contract”).
Please feel free to call if you have questions or need additional information.
Best regards, Lori Donohue Contracts Manager INO Therapeutics LLC d/b/a Mallinckrodt
(908) 238-6668 critcare-contracts@mnk.com http://www.mallinckrodt.com/
File details come from the government source that posted it. Updated .